"IHH has clear growth drivers ahead of it, leveraging on higher demand and revenue intensity, especially in India and Malaysia. Valuations are also ripe for a re-rating, in our view," state the analysts in their Dec 27 note, where they expect IHH to deliver 3-year forward revenue and EBITDA CAGR of 13%.
Maybank Securities has resumed coverage of IHH Healthcare (SGX:Q0F
) , with a "buy" call and sum-of-the-parts based RM7.97 target price for its Bursa-quoted shares, up from a previous target of RM7.13. IHH Healthcare is traded on the Singapore Exchange (SGX:S68) as well.
Year to date, its shares has surged by more than a fifth. Even so, Maybank analysts Yin Shao Yang and Nur Natasha Ariza believe there are reasons to "track" the healthcare giant in the coming year.
